Sequent Extended Study

Sequent Please Neo Extended Post-Market Clinical Follow-up Study

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.

The objective of this multicenter, prospective, non-randomized, postmarket clinical follow-up(PMCF) study is to confirm and support the clinical safety and performance of the Sequent Please Neo in a NON-SELECTED, Real Word population under daily clinical practice when used as intended by the manufacturer to meet EU Medical Device Regulation requirements for post-market clinical follow-up.

Inclusion Criteria:

• Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.
• Informed Consent Signed.

Exclusion Criteria:

• Patient life expectancy less than 12 months.
• Contraindication for antiplatelet therapy.
• Not meet inclusion criteria.